礼来(LLY.US)米吉珠单抗注射液新适应症上市申请获CDE受理

智通财经网2025-04-16

今日，中国国家药监局药品审评中心（CDE）官网最新公示，礼来公司(LLY.US)（Eli Lilly and Company）申报的米吉珠单抗注射液（mirikizumab）以及其皮下注射剂型的新适应症上市申请获得受理。公开资料显示，这是礼来研发的IL-23抑制剂，该疗法曾被Evalulate列为10大潜在重磅疗法之一。该药在中国的首个上市申请于去年10月获得CDE受理，针对适应症为克罗恩病。根据...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2527532245?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-16 21:13","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2527532245","market":"other","top_or_hot":-1,"title":"礼来(LLY.US)米吉珠单抗注射液新适应症上市申请获CDE受理","media":"智通财经网","content":"<div>\n<p>今日，中国国家药监局药品审评中心（CDE）官网最新公示，礼来公司(LLY.US)（Eli Lilly and Company）申报的米吉珠单抗注射液（mirikizumab）以及其皮下注射剂型的新适应症上市申请获得受理。公开资料显示，这是礼来研发的IL-23抑制剂，该疗法曾被Evalulate列为10大潜在重磅疗法之一。该药在中国的首个上市申请于去年10月获得CDE受理，针对适应症为克罗恩病。根据...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-16/doc-inetkpat4324726.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来(LLY.US)米吉珠单抗注射液新适应症上市申请获CDE受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来(LLY.US)米吉珠单抗注射液新适应症上市申请获CDE受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-16 21:13 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-16/doc-inetkpat4324726.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>今日，中国国家药监局药品审评中心（CDE）官网最新公示，礼来公司(LLY.US)（Eli Lilly and Company）申报的米吉珠单抗注射液（mirikizumab）以及其皮下注射剂型的新适应症上市申请获得受理。公开资料显示，这是礼来研发的IL-23抑制剂，该疗法曾被Evalulate列为10大潜在重磅疗法之一。该药在中国的首个上市申请于去年10月获得CDE受理，针对适应症为克罗恩病。根据...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-16/doc-inetkpat4324726.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0203202063.USD","symbol_name":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-16/doc-inetkpat4324726.shtml","article_id":"2527532245","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527532245","pubTimestamp":1744809180,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"今日，中国国家药监局药品审评中心官网最新公示，礼来公司申报的米吉珠单抗注射液以及其皮下注射剂型的新适应症上市申请获得受理。截图来源：CDE官网米吉珠单抗是一款人源化IgG4单克隆抗体，可与IL-23的p19亚基结合，阻断IL-23介导的炎症反应。根据礼来此前新闻稿，这是首个用于治疗这一患者群体的IL-23p19拮抗剂。2025年1月，米吉珠单抗再次获FDA批准，用于治疗成人中度至重度活动性克罗恩病。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","CDE":"科尔黛伦矿业","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LLY":"礼来","BK4017":"黄金","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4599":"减肥药","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK4534":"瑞士信贷持仓","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC"},"translate_title":"Eli Lilly's (LLY.US) marketing application for new indications of miquizumab injection was accepted by CDE","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDE":1,"CDEDC":1,"LLY":1},"content_text":"今日，中国国家药监局药品审评中心（CDE）官网最新公示，礼来公司(LLY.US)（Eli Lilly and Company）申报的米吉珠单抗注射液（mirikizumab）以及其皮下注射剂型的新适应症上市申请获得受理。公开资料显示，这是礼来研发的IL-23抑制剂，该疗法曾被Evalulate列为10大潜在重磅疗法之一。该药在中国的首个上市申请于去年10月获得CDE受理，针对适应症为克罗恩病。根据公开资料推测，本次该药申报上市的适应症为可能为治疗中重度活动性溃疡性结肠炎（UC）成人患者。截图来源：CDE官网米吉珠单抗是一款人源化IgG4单克隆抗体，可与IL-23的p19亚基结合，阻断IL-23介导的炎症反应。作为一种炎性细胞因子，IL-23参与了多个炎症相关的生理过程，被认为与许多免疫介导的慢性疾病有关，也因此成为了许多自身免疫性疾病的治疗靶点。2023年10月，美国FDA批准米吉珠单抗用于治疗中重度活动性溃疡性结肠炎（UC）成人患者。根据礼来此前新闻稿，这是首个用于治疗这一患者群体的IL-23p19拮抗剂。该产品治疗溃疡性结肠炎开始时静脉输注300毫克，每4周输注一次，共输注3次，在维持治疗期间，每4周进行两次100毫克皮下注射。2025年1月，米吉珠单抗再次获FDA批准，用于治疗成人中度至重度活动性克罗恩病（CD）。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2527532245","isCrawlerRequest":true}